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Andre Wolterbeekc, Jacky Van Gompela, Peter De Witteb* and
Camila V. Esguerrab*‡,ABSTRACT: Drug-induced liver injury (DILI) is poorly predicted by single-cell-based assays, probably because of the lack of
physiological interactions with other cells within the liver. An intact whole liver system such as one present in zebrafish larvae
could provide added value in a screening strategy for DILI; however, the possible occurrence of other organ toxicities and the
immature larval stage of the zebrafish might complicate accurate and fast analysis. We investigated whether expression
analysis of liver-specific fatty acid binding protein 10a (lfabp10a) was an appropriate endpoint for assessing hepatotoxic effects
in zebrafish larvae. It was found that expression analysis of lfabp10awas a valid marker, as after treatment with hepatotoxicants,
dose–response curves could be obtained and statistically significant abnormal lfabp10 expression levels correlated with
hepatocellular histopathological changes in the liver. However, toxicity in other vital organs such as the heart could impact liver
outgrowth and thus had to be assessed concurrently. Whether zebrafish larvae were suitable for assessing human relevant
drug-induced hepatotoxicity was assessed with hepatotoxicants and non-hepatotoxicants that have been marketed for human
use and classified according to their mechanism of toxicity. The zebrafish larva showed promising predictivity towards a number
of mechanisms and was capable of distinguishing between hepatotoxic and non-hepatotoxic chemical analogues, thus implying
its applicability as a potential screening model for DILI. Copyright © 2015 John Wiley & Sons, Ltd.
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Drug-induced liver injury (DILI) represents a major challenge for
clinicians, the pharmaceutical industry and regulatory authorities,
as it is a major problem in both the early and later stages of the
drug development process, and the most frequent cause of post-
marketing warnings and withdrawals (Kaplowitz, 2005; MacDonald
and Robertson, 2009; Schoonen et al., 2009). Its strategic location
and prominent role in the metabolism of xenobiotics renders the
liver particularly susceptible to potential toxic effects of a drug
and/or its metabolites. The parent drug or metabolite can exert
their toxic effect on critical functions in the hepatocytes (e.g. mito-
chondrial) or on drug transporters. In addition, electrophilic metab-
olites or free radicals may deplete glutathione (GSH), bind to
proteins and/or lipids, or induce lipid peroxidation (Guengerich
and Shimada, 1991; Jollow et al., 1973). The consequences include
hepatocellular necrosis, apoptosis and sensitization to cytokine or
inflammatory mediators produced by non-parenchymal cells of
the liver. Alternatively, the reactivemetabolitesmay covalently bind
to liver proteins changing their structure and, among others, lead-
ing to sensitization and immune-mediated injury. DILI is further
complicated by the interplay of genetic and environmental risk fac-
tors that influence the susceptibility of individuals (Kaplowitz, 2007).
The series of different underlying mechanisms, complexity of
interaction with different cell types and differences in species-
and patient susceptibility are the primary reasons DILI in humans
is not accurately predicted today. In addition, it is highly unlikely
that one single in vitro or in vivo system would predict allJ. Appl. Toxicol. 2015 Copyright © 2015 John Wiley & Sons, Ltd.
N. Mesens et al.mechanisms. Strategies to predict DILI would therefore benefit
from a panel of assays, predicting different mechanisms at differ-
ent stages of drug development, according to their throughput
and complexity (Godoy et al., 2013).
A strategy to develop drugs that have the highest margin of
safety uses early screening assays to identify and eliminate phar-
maceuticals with the potential to cause severe liver injury (Hill
et al., 2012). Most screening approaches consist of profiling drugs
in a panel of mechanistically relevant in vitro assays detecting
cytotoxicity, mitochondrial injury, transporter inhibition and reac-
tive metabolite formation before drug candidates enter the
in vivo preclinical testing phase (Stepan et al., 2011; Thompson
et al., 2012). However, the predictive capacity of the currently used
in vitro assays remains low because of the poor physiological cor-
relation between the immortalized cell lines generally used and
the human hepatocytes as they exist in their native state (Hartung
and Daston, 2009). In addition, single cells in vitro lack the interac-
tions with other cells within the liver that are often required to am-
plify the initial toxicological lesion into overt toxicity. New
developments in this area include co-cultures of hepatocytes with
non-parenchymal cells cultured under carefully controlled condi-
tions, and the use of specialized bioreactors that reconstitute the
three-dimensional cell architecture and take into account liquid
flow (Khetani and Bhatia, 2008; Wang et al., 2010; Zeilinger et al.,
2011). However, the complexity of the conditions and methodolo-
gies are time consuming and yield very low throughput; incom-
patible with the fast cycling times of the drug discovery process.
An alternative approach is the use of the whole liver system of
zebrafish larvae, with unique advantages for earlymedium through-
put in vivo toxicity screening that can precede preclinical toxicity
testing. Zebrafish larvae are only 1–4mm long and can live in a
single well of a 96-well plate for several days (Sukardi et al., 2011).
They are inexpensive to maintain, easily bred in large numbers
and organogenesis is completed by 72h post-fertilization (hpf)
(Chakraborty et al., 2009; Isogai et al., 2001; Pack et al., 1996). Unfor-
tunately, in contrast to our highly advanced knowledge onmolecu-
lar developmental genetics in zebrafish, our knowledge regarding
non-neoplastic hepatotoxicity lags far behind the information avail-
able for most other mammalian species (Spitsbergen and Kent,
2003). Physiology and responses to toxicants must be understood
in detail beforewe can appreciate the potential of the zebrafish liver
as a model for human hepatotoxicity (Menke et al., 2011).
Physiologically, the liver of adult and larval zebrafish is responsi-
ble for the same basic metabolic functions as in mammals, includ-
ing processing and storage of nutrients, the synthesis of enzymes
and other cofactors, bile formation and excretion, lipogenesis and
the metabolism of xenobiotic compounds (Chu and Sadler, 2009).
Zebrafish have analogous mechanisms for handling xenobiotic
compounds, including both phase 1 and phase 2 biotransforma-
tion (Alderton et al., 2010; Jones et al., 2010). In the larval stage,
expression of genes indicative of hepatocyte function is first
detectable by 32hpf, and hepatic outgrowth begins at 72 hpf. At
5 days post-fertilization (dpf), bile production, serum protein secre-
tion, glycogen storage, lipogenesis and xenobiotic metabolism are
fully operational (Chu and Sadler, 2009). All cell types are present
in the larval zebrafish liver, except for Kupffer cells, which are re-
placed by macrophages (Chu and Sadler, 2009).
Morphological liver changes have been observed in genemuta-
tion experiments. Mutations in the genes foie gras, the tumor sup-
pressor gene nf2 and the class C vacuolar protein sorting gene
vps18 result in phenotypes resembling different liver diseases such
as hepatic steatosis, choledochal cysts and cholestasis, respectivelyCopyright © 2015 Johnwileyonlinelibrary.com/journal/jat(Sadler et al., 2005). In addition, γ-hexachlorocyclohexane,
thioacetamide and alcohol can induce hepatic steatosis (Amali
et al., 2006; Braunbeck et al., 1990; Passeri et al., 2009). Another
well-described pathologic response of the fish liver to toxins is he-
patocellular necrosis, with a random pattern of single-cell necrosis
(Hinton et al., 2001). Macroscopically, massive hepatocellular ne-
crosis can result in smaller, dark livers owing to the loss of transpar-
ency and these have been suggested as a phenotypic endpoint for
assessing hepatotoxicity (Hill et al., 2012). As significant wide-
spread liver necrosis is necessary before it can be observedmacro-
scopically, this phenotypic endpoint is reported to be insensitive
for detecting early hepatotoxic events (Wolf and Wolfe, 2005).
The aim of this study was to evaluate the applicability of
zebrafish larvae for assessing the drug-induced hepatotoxicity
potential of drug candidates. To circumvent the use of pheno-
typic darkening of the liver, a molecular endpoint was chosen
that could detect as many mechanisms of hepatotoxicity as possi-
ble, was not limited to cell death, but also included effects on lipid
metabolism, as insults on the liver are frequently associated with a
perturbation in lipid metabolism (Kaplowitz, 2007). Hereto, the
expression of the liver specific fatty acid binding protein 10a
(lfabp10a) was chosen as a marker, as mammalian LFABP10 has
a central role in different aspects of liver lipid metabolism: it
extracts long chain fatty acids-coenzyme A (LCFA-CoAs) from
and transfers LCFA-CoAs between membranes, enhances LCFA-
CoA transesterification to phospholipids, cholesteryl esters and
triglyceride storage and might stimulate LCFA-CoA oxidation
(Martin et al., 2003). In addition, LFABP transports LCFAs to the
nucleus for regulation of nuclear receptors important in transcrip-
tion of genes encoding proteins involved in LCFA and glucose
metabolism, such as peroxisome proliferator-activated receptor
α (PPAR-α), hepatocyte nuclear factor-4 (HNF-4) and liver X recep-
tor (LXR) (Atshaves et al., 2010). Lfabp10a is exclusively present in
the liver, expressed at very high levels in hepatocytes and
reported to constitute 1–5% of the cytosolic protein of the liver
(Atshaves et al., 2010; Venkatachalam et al., 2009); enabling
sensitive analysis of liver-specific lipid-related effects. Moreover,
an investigation of proteomic biomarkers in in vivo hepatotoxicity
in rats showed that the LFABP proteins are down-regulated after
Acetaminophen exposure, suggesting lfabp10 is downregulated
during acute hepatocellular necrosis (Yamamoto et al., 2006).
Furthermore, North et al. (2010) showed that lfabp10a expression
effectively diminishes in zebrafish larvae treated with the
hepatotoxicant acetaminophen, indicating that acetaminophen-
induced hepatocellular necrosis is indeed accompanied with a
downregulation of lfabp10a expression.
The effect of a number of well-characterized human relevant
reference compounds on lfabp10a expression was then investi-
gated. Reference compounds were selected to induce the major-
ity of hepatotoxic phenotypes in humans (cholestasis, steatosis
and necrosis) with well-described putativemechanisms of toxicity
such as inhibition of the bile salt export pump (BSEP), mitochon-
drial toxicity and reactivemetabolite formation. Compoundswere
divided in hepatotoxicants and non-hepatotoxicants, according
to the observed hepatotoxicity in humans, and sensitivity was in-
vestigated. To ensure detection of toxic effects on both the ex-
pression of lfabp10a and potential morphological changes of
the liver, in situ hybridization on lfabp10a was performed and lar-
vae were scored through amicroscope. Concurrently, other organ
toxicities were recorded, to investigate the specificity of the liver
response. A subset of compound-treated larvae was subjected
to histopathological analysis to determine whether we couldJ. Appl. Toxicol. 2015Wiley & Sons, Ltd.
DILI in zebrafish larvaecorrelate changes to lfabp10a expression with a potential patho-
logic response. Finally, predictivity was assessed and a correlation
with the mechanisms of toxicity was determined.Materials and Methods
Animals: Zebrafish Larvae
AB strainwild-type zebrafish (Danio rerio) weremaintained and bred
at 28 °C in the facilities formore than five generations. Zebrafish em-
bryos were collected through natural spawning. Briefly, adult male
and female zebrafish were kept together in an aquarium on a
14/10-h day/night light cycle with ‘egg traps’ placed at the bottom
of the tanks. Spawning behavior normally commenced shortly after
light activation in the morning. All eggs were checked for quality
(e.g. high percentage of fertilization, clear cytoplasm and symmet-
ric cleavage). All eggs were checked to be fertilized and thereafter
pooled in a single Petri dish containing 0.3×Danieau’s solution
(17mM NaCl, 2mM KCl, 0.12mM MgSO4, 1.8M Ca(CaNO3)2 and
1.5mM HEPES, pH7.6) until the start of the exposure.Chemicals
1. lfabp10a probe
A full-length cDNA clone was obtained for zebrafish lfabp10a
(IMAGE number 7080902, GenBank accession number BC076219),
and its identity confirmed by 5’ and 3’ sequence tags. This clone
is in the plasmid pME18S-FL3, whichwas linearized byNotI and sub-
jected to an in vitro transcription reaction using T7 RNA polymerase
to generate an antisense, digoxigenin labeled lfabp10a probe.
Multiple sequence alignments of lfabp10a and fabp1 clademem-
bers were carried out using ClustalW2, version 2.0.12, of EMBL-EBI.
2. Drugs: selection and characterization
Fourteen compounds that have been marketed for use in
humans were assessed for their hepatotoxicity potential and
classified into hepatotoxic or non-hepatotoxic. Non-hepatotoxicity
was ascribed to the four drugs Zolpidem, Buspirone, Ketorolac and
Rosiglitazone, which were synthesized as chemically closely-
related analogues of the human hepatotoxic compounds Alpidem,
Nefazodone, Diclofenac and Troglitazone, having a much better
clinical safety profile, and which have largely replaced the hepato-
toxic analogues for human use (obtained from http://livertox.nlm.
nih.gov/). The 10 hepatotoxic drugs were classified into three cat-
egories according to the predominant phenotypic manifestation
of hepatotoxicity observed in humans (cholestasis, steatosis and
necrosis) (obtained from http://livertox.nlm.nih.gov/) (see Table 1).
In addition, the well-described or suggested mechanism of DILI
was characterized by a thorough literature research in Kaplowitz
(2005) and Stepan et al. (2011); the compound labeling informa-
tion and http://www.drugbank.ca/.Source and Supply of Chemicals and Zebrafish
All chemicals used in the study were obtained from Sigma-
Aldrich (Diegem, Belgium).
The full-length cDNA clone of lfabp10a was synthetized by
GeneScript.
The zebrafish wild-type AB strain was originally obtained from
the Zebrafish International Resource Center (ZIRC), University of
Oregon, Eugene, USA.J. Appl. Toxicol. 2015 Copyright © 2015 JohnTreatment: Compound Incubations and Toxicity Assessment
Compounds were first dissolved in DMSO to create a stock solu-
tion and afterwards diluted in Danieau’s solution to a final con-
centration of 1% DMSO w/v. Zebrafish embryos of the AB
wild-type strain were raised at 28 °C. At 3 dpf, hatched larvae
were placed into 24-well plates with 10 larvae and 1ml of 0.3×
Danieau’s solution per well containing the dissolved drug or
the vehicle control. In a first range-finding experiment, the drug
concentration inducing lethality in all larvae after 72-h exposure
was determined, which was then used as the top concentration
in the follow-up experiment. In this follow-up experiment, a se-
rial dilution of the top concentration [Ctop] was used: [Ctop];
[Ctop-1] = [Ctop] /2; [Ctop-2] = [Ctop-1] /2; [Ctop-3] = [Ctop-2] /2;
[Ctop-4] = [Ctop-3] /2 and [Ctop-5] = [Ctop-4] /2.
Larvae were incubated for 72 h with the dissolved drug or the
vehicle control, then fixed and subjected to whole-mount in situ
hybridization with a digoxigenin-labeled zebrafish lfabp10a anti-
sense RNA probe. Stained embryos were scored manually by an
experienced scientist through a stereo dissecting microscope, in
a blinded fashion, by assessing the number of larvae per well
exhibiting an abnormal lfabp10a expression pattern, as defined
by the criterion that the hepatic lfabp10a expression was differ-
ent (smaller in intensity or size; absent or larger) compared with
the predominant hepatic lfabp10a expression in previously
screened control larvae. In addition to this endpoint, other mor-
phological abnormalities and toxicities in other vital organs were
recorded. Larvae were scored for lethality, the occurrence of
edema in the region of the heart, abnormal heart rate or circula-
tion, hemorrhage and body curvatures. Each of these endpoints
was assessed for each concentration and the vehicle control. Ex-
periments were repeated in triplicate, resulting in a total of
30 larvae tested per concentration for each compound.
Statistical Analysis
Statistics were performed on the total number of larvae tested
per concentration per compound (30). Abnormal lfabp10a ex-
pression patterns (reduced expression, reduced size, enlarged
size and absence of expression) were grouped and compared
with the lfabp10a expression pattern of the vehicle controls. Oc-
currence of a dose response and statistical significance of the re-
sponse were then investigated. As for each compound the data
refer to the number of abnormalities out of a total number and
are thus binomially distributed, a logistic model was fitted to
evaluate whether there was a trend between the probability of
abnormality and concentration (Agresti, 2002). In addition, con-
centration was added as a factor in a logistic regression model
and pairwise comparisons versus the vehicle were evaluated.
In order to address the issue of multiple comparisons, P-values
were adjusted using the Bonferroni–Holm correction factor.
When a trend was present, the lowest observed effect level
(LOEL) was defined as the lowest concentration inducing an ef-
fect statistically significant (α= 0.05) from the vehicle controls.Techniques
1. Whole-mount in situ hybridizations
Whole-mount in situ hybridizations were carried out accord-
ing to a previously published protocol (Thisse and Thisse,
2008) with adaptations developed by Schulte-Merker (personal
communication) and colleagues. These latter changes primarilyWiley & Sons, Ltd. wileyonlinelibrary.com/journal/jat
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DILI in zebrafish larvae
J. Appl. Toxicol. 2015 Copyright © 2015 Johninvolve a prolonged proteinase K incubation step, which was
45min in 10mgml1 proteinase K for 6 dpf larvae, and the
manual bifurcation of fixed 6 dpf larvae (at the midpoint of
the yolk sac extension) with a scalpel prior to the initiation of
the in situ protocol, so as to improve the penetration of the
probe and the effectiveness of the washing steps. Liver-specific
expression of lfabp10a during the different days of larval growth
was assessed up to 6 dpf.
2. Histology
After treatment, the larvae were fixed overnight in Bouins fixa-
tive, transferred and then stored in 70% ethanol until use. Sam-
ples were first embedded in a specially-designed 1% agarose
mold for adequate positioning of the embryos (Sabaliauskas
et al., 2006; Tsao-Wu et al., 1998), and then transferred to paraffin.
Thereafter, the larvae were sectioned transversally or saggitally
into 4-μm sections, were routinely stained with hematoxylin and
eosin (H&E) and covered with a glass coverslip. In each experi-
ment, the slides of vehicle control larvae and larvae exposed to ei-
ther 10μM Diclofenac, 5μM Troglitazone, 2.5μM Rosiglitazone or
100μM Alpidem were analyzed by an experienced pathologist.
Both transversal and saggital sections were analyzed to assess
the effects on the liver and overall toxicity. Larvae were cut up
completely and all sections that contained liver tissue were ana-
lyzed. In this way the pathologist built a ‘3D picture’ of the liver
so the size of the liver could be analyzed histologically as well.
Results
Whole-Mount In Situ Hybridization Analysis of lfabp10a
Expression in Control Zebrafish
To generate an antisense in situ probe, we obtained a cDNA clone
(IMAGE number 7080902) that was confirmed by sequence anal-
ysis to encode full-length zebrafish lfabp10a.Whole-mount in situ
hybridization (WISH) analysis of lfabp10a expression in embryos
and larvae on each of the first 6 days of development revealed
the first detectable transcription in the livers of 2 dpf embryos.
No lfabp10a expression was seen in 1 dpf embryos. Increasing
lfabp10a expression levels correlated with liver size and in-
creased progressively at 3, 4 and 5 dpf (results not shown).lfabp10a WISH Analysis of Larvae Treated with Hepatotoxic
Compounds and Toxicity Analysis
Larvae treated with the 10 hepatotoxic compounds showed dif-
ferent lfabp10a expression patterns (Fig. 1). Occasionally, absence
of expression was observed. Sometimes the expression was re-
duced in intensity, whereas the area of expression was compara-
ble to the control liver. On a few occasions, the expression had
the same intensity as the control livers but the area of expression
was larger or smaller, suggesting morphological liver changes as
enlargement of the liver or a reduction in the liver size (Fig. 1). For
the ease of reading the different expression patterns are referred
to as absent expression, reduced expression, enlarged liver size and
reduced liver size, respectively, throughout the manuscript.
Concentration-response curves were obtained and statistical
analysis of occurrence of a trend was performed by logistic re-
gression comparing the proportion of larvae showing an abnor-
mal lfabp10a expression at different concentrations to the
controls (Table 2). A concentration response trend was obviousWiley & Sons, Ltd. wileyonlinelibrary.com/journal/jat
AB
C
D
E
Figure 1. Different lfabp10a expression patterns observed in 6 days
post fertilization larvae. (A) Normal expression. (B) Reduced expression.
(C) Reduced size. (D) Absent expression. (E) Enlarged size.
N. Mesens et al.for most of the hepatotoxic compounds: Tetracycline, Acetamin-
ophen, Amiodarone, Bosentan, Tacrine, Alpidem, Diclofenac and
Troglitazone, but was absent for Tamoxifen and Nefazodone; as
shown by the Trend test P-value (Table 2). In contrast, a concen-
tration-response trend was not present in case of the non-
hepatotoxic compounds Zolpidem, Buspirone and Ketorolac,Copyright © 2015 Johnwileyonlinelibrary.com/journal/jatexcept for Rosiglitazone. When a trend was present, the LOEL
was calculated by a pairwise comparison of the proportion of
larvae showing an abnormal lfabp10a expression at a specific
concentration to the controls (Table 2). The LOEL could be cal-
culated for all compounds except for Tamoxifen, Bosentan and
Ketorolac. In the case of Zolpidem, Nefazodone and Buspirone,
an LOEL could be calculated, although a trend was not pres-
ent in their concentration response curves (Table 2).
The predominant expression pattern observed in affected
larvae was reduced expression (treatment with Tetracycline,
Acetaminophen, Zolpidem, Nefazodone, Diclofenac, Ketorolac,
Troglitazone and Rosiglitazone). Occasionally, this was accompa-
nied with reduced liver size or absent expression (treatment with
Amiodarone and Nefazodone). Remarkably, enlarged liver size
and reduced expression could be observed in the same dosing
groups (treatment with Acetaminophen and Tetracycline, Alpidem
and Zolpidem) (Fig. 2). In the vehicle control group, abnormal
lfabp10a expression was occasionally observed. Of the 614 control
larvae, 99 (16%) larvae were scored with a reduced expression and 5
(0.8%) larvae had an enlarged size (results not shown).
Concurrent other organ toxicities were mainly effects on car-
diac function and circulation, increase in edema and body curva-
ture (Table 3). Most organ toxicities occurred at concentrations
higher than the LOEL for DILI, except for Rosiglitazone and
Alpidem, which induced hemorrhage and a slow heartbeat and
edema and a rapid heartbeat, respectively (Table 3). In the vehi-
cle control group, minor organ toxicities occurred, ranging from
0.32% of the larvae presenting with hemorrhaging or body curv-
ing to 0.64% of the larvae having edema (Table 3).
Subsequently, histopathological examinations were per-
formed to study potential pathological effects that correlated
with changes observed in lfabp10a expression, as well as the in-
fluence of other microscopic organ toxicities on changes in
lfabp10a expression.Endpoint Confirmation with Histology
In an effort to validate abnormal lfabp10a expression with histo-
logical correlates, the livers of Diclofenac-, Troglitazone-,
Rosiglitazone- and Alpidem-treated larvae, and their controls,
were analyzed histopathologically. No abnormalities could be
detected in the control livers. Glycogen levels differed between
individual control larvae but overall a very similar distribution
was observed in each experiment (Fig. 3). In addition, no differ-
ences were observed between untreated larvae and larvae
treated with the DMSO vehicle control (results not shown). Po-
tential correlations between abnormal lfabp10a expression and
a pathogenic liver response were investigated with 10μM
Diclofenac and 5μM Troglitazone as these compounds showed
marked effects on the expression of lfabp10a. Specificity of
lfabp10a expression was investigated with 2.5μM Rosiglitazone
and 100μM Alpidem as both compounds induced concurrent
effects on circulation and heart rate at the concentrations induc-
ing effects on the lfabp10a expression (Table 3).
Diclofenac and Troglitazone. In the lfabp10a assay, 6% of the
larvae treated with 10μM Diclofenac (n=50) were scored with
a reduced expression, 36% with a reduced liver size and 2 % with
absent expression (results not shown). Histopathological analysis
of both transversally-(n=25) and saggitally-(n=25) sectioned
larvae, revealed that in 12% of the larvae the livers showed a
moderate hepatocellular glycogen accumulation (Fig. 4B) thatJ. Appl. Toxicol. 2015Wiley & Sons, Ltd.
Table 2. Results of the logistic regression analysis
Trend test P-
value
Pair-wise comparisons: Bonferroni–Holm adjusted P-value LOEL
(μM)
conc
(μM)
P-value
conc
(μM)
P-value conc
(μM)
P-value conc
(μM)
P-value conc
(μM)
P-value
Tamoxifen NS 0.625 NS 1.25 NS 2.5 NS 5 NS 10 NS /
Tetracycline <.0001 25 NS 50 NS 100 <.05 200 <.001 100
Acetaminophen <.0001 25 NS 50 NS 100 <.0001 200 <.01 100
Amiodarone <.001 1.25 NS 2.5 <.05 5 <.01 2.5
Bosentan <.005 12.5 NS 25 NS 50 NS 100 NS 200 NS /
Tacrine <.0001 12.5 <.0001 25 <.0001 50 <.0001 100 <.0001 12.5
Alpidem <.0001 12.5 <.001 25 <.0001 50 <.0001 100 <.0001 12.5
Zolpidem NS 12.5 NS 25 NS 50 NS 100 NS 200 <.05 200 (*)
Nefazodone NS 1.25 NS 2.5 NS 5 NS 10 NS 5 (*)
Buspirone NS 12.5 <.01 25 <.01 50 <.01 100 NS 200 <.01 12.5(*)
Diclofenac <.01 2.5 NS 5 <.05 100 <.05 5
Ketorolac NS 12.5 NS 25 NS 50 1 100 NS /
Troglitazone <.001 1.25 NS 2.5 <.05 5 <.01 10 <.01 2.5
Rosiglitazone <.001 1.25 NS 2.5 <.05 5 <.05 10 NS 2.5
Trend test P-value: Trend in concentration response curve is present when P <0.05. NS: not significant. Pair-wise comparisons:
Bonferroni–Holm adjusted P-value: concentration induces statistically significant effect when P<0.05. For more details refer to text
and materials and methods. LOEL: lowest observed concentration inducing a statistical significant effect. (*) LOEL was calculated
although trend test was not significant.
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Figure 2. lfabp10a expression dose–response curves obtained after treatment with the 14 compounds. Closed circles represent normal expression.
Open triangles represent reduced expression. Open squares represent reduced size. Crosses represent absent expression. Open diamonds represent en-
larged size.
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Table 3. Concentration of the drug inducing other organ toxicities in zebrafish larvae recorded on day 6 before in situ
hybridization
compound LOEL Liver concurrent organ toxicities
edema heart beating-
circulation
hemorrhage body
curvatures
death green
galbladder
enlarged
swimbladder
Solvent (1%
DMSO)
/ 0.64% 0% 0.32% 0.32% 0% 0% 0%
Tamoxifen / 10μM rapid
(90%)
10μM
(100 %)
5μM (10%) 10μM (33%)
Tetracycline 100μM 500μM (33%)
Acetaminophen 100μM 200μM (30%) 500μM (100 %)
Amiodarone 2.5μM 10μM (100 %)
Bosentan / 200μM (15%)
Tacrine 12.5μM 50μM (70 %) 200μM
(100 %)
100μM (100 %)
Alpidem 12.5μM 10μM
(30%)
10μM (30%) 25μM (90%) 200μM
(100 %)
Zolpidem 200μM (*) 25μM (50%) 500μM
(100%)
Nefazodone 5μM (*) 10μM (50 %) 20μM
(100 %)
Buspirone 12.5μM (*) 200μM
(100 %)
25μM (20 %)
Diclofenac 5μM 10μM
(30 %)
10μM slow
(70 %)
10μM
(36 %)
Ketorolac / 100μM rapid
(80 %)
50μM (20 %) 200μM
(100 %)
Troglitazone 2.5μM 12.5μM
(100 %)
Rosiglitazone 2.5μM 2.5μM (40%) 2.5μM
(40%)
25μM
(70 %)
Results represent the mean of three experiments. LOEL liver: lowest observed effective concentration producing a statistically sig-
nificant effect on lfabp10a expression. Concurrent organ toxicities: the concentration at which the toxicity occurs and the percent-
age of larvae showing the toxicity is indicated. (*) LOEL was calculated although trend test was not significant.
N. Mesens et al.was absent in the controls (Fig. 4A). Furthermore, in 10% of the
larvae, the livers were small with hypertrophic hepatocytes,
showing mild vacuolation (Fig. 4C). The presence of these small
livers correlated with edema in the larvae. In addition, in 40% of
the larvae, tubular necrosis was observed in the pronephros (ar-
row in Fig. 4D). In agreement with the lfabp10a expression pat-
tern, indicative of predominantly a reduced liver size (36%),
histopathological analysis showed a reduction in liver size
(10%), albeit with a lower incidence.
In the lfabp10a assay, 36% of the larvae treated with 5μM
Troglitazone (n= 50) were scored with a reduced expression and
24% with a reduced liver size (results not shown). Histopatholog-
ical analysis of both the transversally-(n= 25) and the saggitally-
(n=21) sectioned larvae showed that in about 11% of the cases,
the liver was small with hypertrophic hepatocytes, showing min-
imal vacuolation with an enlarged nucleus and a prominent nu-
cleolus (Fig. 5B, 5C) as compared with the concurrent analyzed
controls (Fig. 5A). Similar to the larvae exposed to diclofenac,
the presence of these small livers correlated with edema in the
larvae. In agreement with the lfabp10a expression pattern, indic-
ative of a reduced liver size (24%), histopathological analysis also
showed a reduction in liver size (11%), albeit with a lower
incidence.Copyright © 2015 Johnwileyonlinelibrary.com/journal/jatRosiglitazone and Alpidem. In the lfabp10a assay, 26% of the
larvae treated with 2.5μM Rosiglitazone (n= 50) were scored
with a reduced expression and 4% with a reduced liver size
(results not shown). In addition, visual assessment of other
organ toxicities indicated that about 40% of the treated larvae
presented with effects on the heart beat frequency and
hemorrhaging (Table 2). Histopathological analysis of the both
the transversally-(n= 24) and the saggitally-(n=19) sectioned
larvae revealed no hepatocellular abnormalities. In agreement
with the lfabp10a expression patterns, analysis of the transver-
sal sections, indicated that in 36% of the larvae, the liver lobes
were shorter, in a rostral-caudal direction compared with those
of the controls (P< 0.0001). The hepatocytes, however, were
normal and comparable with controls (Fig. 6B, A). The length
of the liver lobes was difficult to assess in the saggitally-
sectioned larvae (Fig. 6C). No effects were observed in the
hepatocytes.
In the lfabp10a assay, 4% of the larvae treated with 100μM
Alpidem (n=50) were scored with reduced expression, whereas
80% of the larvae were scored with an enlarged liver (results not
shown). In addition, visual assessment of other organ toxicity in-
dicated that about 30% of the treated larvae had an increased
heart rate and edema (Table 3). In agreement with the lfab10aJ. Appl. Toxicol. 2015Wiley & Sons, Ltd.
BA C
Figure 4. (A) Transversal H&E liver sections of a control larva and a Diclofenac-treated larva showing moderate accumulation of glycogen in the liver
(B) or a small liver (C) with hypertrophic, vacuolated hepatocytes (fat arrows). Yellow border indicates the liver. (D) Detailed image from (C) showing the
vacuolization. Magnification: 400×.
BA
DC
Figure 3. Hepatocellular glycogen variation in control livers. Histopathological analysis of transversal HE sections of control larvae showing varying
levels of glycogen accumulation from no observable accumulation (A), to minimal (B), very mild (C) and mild accumulation (D). Yellow border indicates
the liver. Magnification 400×.
BA C
Figure 5. Transversal H&E liver section of a control larva (A) and Troglitazone-treated larva showing a small liver (B) with hypertrophic, vacuolated
hepatocytes (fat arrows), in combination with edema (thin arrows). Saggital section of a Troglitazone-treated larva showing a small liver (C) with hy-
pertrophic, vacuolated hepatocytes (fat arrow), in combination with edema (thin arrows). Yellow border indicates the liver. Magnification: 400×.
A B C
Figure 6. Transversal H&E liver slides of a control larva (A) and a Rosiglitazone-treated larva (B). Hepatocytes in the liver of the Rosiglitazone-treated
larva are normal and comparable to the controls. (C) Saggital H&E section of a Rosiglitazone-treated larva. No hepatocellular abnormalities are observed.
DILI in zebrafish larvae
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N. Mesens et al.expression data, histopathological analysis of both the
transversally-(n=25) and the saggitally-(n= 19) sectioned larvae,
showed that in 85% of the larvae, the liver was enlarged (Fig. 7B–D)
compared with the controls (Fig. 7A). In 5% of these cases, the
hepatocytes were vacuolated (Fig. 7C). In the remaining 80% of
the cases, the hepatocytes were not obviously hypertrophic, sug-
gesting that the enlargement was due to hyperplasia. The hepato-
cellular cytoplasm of these livers was eosinophilic and the glycogen
content appeared to be reduced, giving the liver a compact ap-
pearance. In agreement with the morphologically observed peri-
cardial edema (30%), pericardial edema was also observed
histopathologically, albeit with a lower percentage (5%).
Predictivity Testing
Steatosis-inducers: Tamoxifen, Tetracycline and Amiodarone. Ex-
cept for Tamoxifen, the steatosis-inducers produced a
concentration-dependent effect on lfabp10a expression (Fig. 2).
A Tetracycline-related increase in lfabp10a expression was prob-
ably due to its inhibitory effects on microsomal transfer protein
(Table 1). Amiodarone in contrast caused a concentration-
dependent decrease in lfabp10a expression, possibly due to its
effect on the mitochondrial membrane and uncoupling of oxida-
tive phosphorylation, inducing apoptosis and necrosis, which
precedes or accompanies its inhibitory effect on the mitochon-
drial β-oxidation (Table 1). Tamoxifen has been shown to induce
the same effects on mitochondrial physiology but its pharmaco-
logical antiproliferative properties also induced a general toxic
response in zebrafish larvae that preceded its hepatotoxic ef-
fects (Table 1).
Cholestasis-inducer: Bosentan. Bosentan, a human-specific cho-
lestasis inducer due to its inhibitory effects on the biliary salt ex-
port pump, did not produce effects on the lfabp10a expression
patterns (Fig. 2).
Oxidative stressors/ reactive metabolite formation: Acetamino-
phen, Tacrine and Diclofenac. Acetaminophen, Tacrine and
Diclofenac, forming reactive metabolites, all produced a signifi-
cant change in lfabp10a expression. Predominantly, a reduction
in lfabp10a expression was observed by the co-occurrence of re-
duced expression, reduced liver size and absent expression after
treatment with Tacrine and Diclofenac. However, treatment with
Acetaminophen resulted in a co-occurrence of both reduced ex-
pression and enlarged liver size (Fig. 2).
Multiple mechanisms: Alpidem, Nefazodone and Troglitazone.
The remaining hepatotoxic compounds Alpidem, Nefazodone
and Troglitazone induce hepatotoxicity via a combination of
mechanisms encompassing reactive metabolite formation and
mitochondrial toxicity. All compounds exerted a concentration-A B
Figure 7. Transversal H&E liver section of a control larva (A) and an Alpidem
or hypertrophic vacuolated hepatocytes (C). Saggital H&E section of an Alpid
sia and edema (arrows) (D). Yellow border indicates the liver. Magnification:
Copyright © 2015 Johnwileyonlinelibrary.com/journal/jatdependent effect on lfabp10a expression; although a trend was
absent in the concentration-response curve of Nefazodone. Re-
duced expression was the predominant expression pattern after
treatment with Nefazodone and Troglitazone, whereas an en-
larged liver size was observed after treatment with Alpidem
(Fig. 2).
Ranking power of chemical analogues. When comparing chem-
ical analogues, a clear difference in LOEL was observed for the
less/non-toxic analogues of Nefazodone, Diclofenac and
Alpidem: Buspirone, Ketorolac and Zolpidem respectively. How-
ever, a clear difference between the potencies of the effects
caused by Troglitazone and its markedly less toxic analogue
Rosiglitazone was not observed.
Overall predictivity and safety margins. Apart from Tamoxifen
and Bosentan, for which compounds the LOEL could not be cal-
culated, the LOEL values obtained in the fabp10a assay of the
human hepatotoxic compounds used in this study were in the
same order of magnitude as the therapeutic dose that induces
hepatotoxicity in patients (Table 1). When safety windows were
calculated based on the difference between the LOEL and the
therapeutic dose, very narrow windows were calculated for the
hepatotoxic compounds which were all smaller or comparable
to 10. In contrast, the safety margins of the non-hepatotoxic
compounds were much larger: ranging from 96 to 307. The only
exception was Rosiglitazone, which had a small safety margin of
11.2 (Table 1).Discussion
Zebrafish larvae are as accessible and proliferative as in vitro cell
cultures, but also provide a complex, in vivo, functional verte-
brate model system (Vliegenthart et al., 2014). This unique com-
bination of attributes makes zebrafish larvae an attractive model
to study drug-induced hepatotoxicity, as at this time, no in vitro
cell model is capable of mimicking the complexity of a whole
liver system. However, the zebrafish model of liver toxicity has
been utilized less frequently (Hill et al., 2012) and as a lower
whole organism with potential other target organs of toxicity
that has not reached mature stage, potential application of the
larval stage for human relevant hepatotoxicity assessment must
be cautiously evaluated.
To investigate whether zebrafish larvae could be a valuable
tool for assessing the hepatotoxicity potential of drug candi-
dates, we therefore applied in situ hybridization on lfabp10a to
explore thoroughly different responses of the zebrafish liver to
hepatotoxicants and to analyse the liver morphology and ex-
pression of lfabp10a in each larva separately, in combination
with potential other organ toxicities. It was found that otherC D
-treated larva showing enlarged livers with hepatocellular hyperplasia (B)
em-treated larva showing an enlarged liver with hepatocellular hyperpla-
400×.
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DILI in zebrafish larvaemorphological abnormalities like body curvatures did not inter-
fere with the analysis, however toxicities in other vital organs
could impact liver morphology and thus the endpoint used. His-
topathological analysis on the livers of the treated larvae
showed a smaller liver after treatment with Rosiglitazone and a
larger liver after treatment with Alpidem, without hepatocellular
effects, thus representing liver growth retardation and accelera-
tion respectively. Indeed, at 70 hpf, or at the start of treatment,
blood circulation is required for the late stages of liver growth
in zebrafish larvae (Korzh et al., 2008) and compounds affecting
the rate of circulation could have a secondary effect on the
growth and size of the liver and thus the lfabp10a expression
pattern. In addition, compounds with antiproliferative properties
like Tamoxifen, failed to induce hepatotoxicity before inducing
general toxicity and lethality in the growing zebrafish larvae.
We next investigated whether lfabp10a expression analysis
was a valid marker for drug-induced hepatotoxicity in zebrafish
larvae. For 8 of the 10 hepatotoxic compounds, a concentration
response could be generated which was dominated by an in-
creased incidence of larvae with a reduced lfabp10a expression
in the liver. Statistical relevant effects could be calculated. To en-
sure that these statistical relevant effects were associated with
histological changes representative of lipid changes, vacuolation
or hepatocellular cell death, histopathological examination of
livers with abnormal expression patterns of lfabp10a was per-
formed. Histopathological analysis of the larval livers treated
with Diclofenac and Troglitazone, inducing predominantly a re-
duction in lfabp10a expression, also showed a smaller liver with
hepatocellular vacuolation and hypertrophy, albeit at a lower in-
cidence. An overall reduction in lfabp10a thus correlated with a
smaller liver and hepatocellular abnormalities, showing that
lfabp10a can be used to screen for these hepatotoxic changes,
as previously suggested by North et al. (2010) and Yamamoto
et al. (2006). In contrast to the previous findings of North et al.
(2010) and Yamamoto et al. (2006), we also observed increases
in lfabp10a expression after drug treatment. Upregulation of
lfabp10a was also present in dose–response curves of many
hepatotoxicants (Acetaminophen, Tetracycline, Amiodarone,
Nefazodone) in the absence of circulation defects. In the dose–
response curves, the concentration inducing an increased ex-
pression in a subset of larvae always induced a decreased ex-
pression in another subset of larvae as well. This increase most
likely coincides with lipid accumulation, as lipid accumulation
is a well-known response in zebrafish to toxicants (Wolf and
Wolfe, 2005), and has been reported to occur after injection of
single dose of Acetominophen (A. Menke, unpublished results).
In addition, a previous study reported the existence of an
inverted profile of two hub biological pathways in response to
chemical perturbations in zebrafish liver (Ung et al., 2011). One
set was primarily associated with lipid metabolism whereas the
other set was composed of non-lipid apoptosis- and
proteasome-related pathways. Upregulation of several lipid reg-
ulated pathways were generally accompanied with down-
regulation of the other set of non-lipid pathways, or vice versa.
This observation parallels the coincidence of up and down regu-
lation of lfabp10a expression in the dose–response curves at the
same concentrations, most likely representing lipid accumula-
tion and induction of apoptosis or necrosis, respectively. In view
of these data, we conclude that lfabp10a is a promising candi-
date zebrafish marker for assessing drug-induced hepatotoxicity.
We next investigated whether the zebrafish larval model is a
good model for assessing the human relevant hepatotoxicityJ. Appl. Toxicol. 2015 Copyright © 2015 Johnpotential of drug candidates. For this evaluation, only drugs that
have been marketed for human use were used. The set of com-
pounds was carefully selected to contain hepatotoxic drugs for
which investigative studies have suggested mechanisms which
could be responsible for, and/or may have contributed to, hu-
man DILI caused by the drugs (mitochondrial toxicity, trans-
porter inhibition and reactive metabolite formation) in order to
assess the capability of zebrafish larvae to identify the different
mechanisms of toxicity. In addition, the set contained four
non-hepatotoxicants that were close chemical analogues of
hepatotoxicants, in order to assess the ranking capability of
zebrafish larvae.Mitochondrial Toxicity – Transporter Inhibition – Reactive
Metabolite Formation
Zebrafish larvae were shown to correctly identify the mitochon-
drial toxic compounds Amiodarone, Tacrine and Tetracycline,
which is not surprising, as all species depend on mitochondria
for the generation of more than 90% of their necessary energy
(Dykens and Will, 2007). However, liver injury was not observed
in zebrafish exposed to Tamoxifen, which previously has been
reported to inhibit mitochondrial functions. It is possible that
this could be due to the antiproliferative effects of this drug on
zebrafish larvae, which may be a consequence of its cytostatic
(G0/G1 arrest) and cytotoxic (induction of apoptosis) action on
cells (Petinaria et al., 2004). Tetracycline produced its hepato-
toxic effects at higher concentrations compared with the thera-
peutic plasma exposure. However, human hepatotoxicity only
occurred with the intravenous dosing schedules, probably
resulting in higher exposures (Kaplowitz, 2005).
In contrast to mitochondrial toxicity, which causes reproduc-
ible toxic effects in different organs across different species
(Dykens and Will, 2007), metabolism-mediated toxic effects can
vary across species, and the capacity of zebrafish larvae to iden-
tify these mechanisms of toxicity must be carefully evaluated.
Most compounds inducing hepatotoxicity via reactive metabo-
lite formation were identified in the zebrafish larvae. Acetamino-
phen, the best understood reactive metabolite-forming
hepatotoxicant, produced obvious effects on lfabp10a expres-
sion with an LOEL of only 100μM. This hepatotoxic effect was
also previously reported by North et al. (2010). Acetaminophen
induced dose-dependent hepatocellular necrosis and depleted
glutathione stores, and the degree of toxicity could be limited
by N-acetylcysteine intervention, a precursor of glutathione. Fur-
thermore, the formation of N-acetyl-p-benzoquinone imine
(NAPQI), the reactive metabolite responsible for the glutathione
depletion, was recently demonstrated in zebrafish larvae by
Chng et al. (2012). In addition, in silico docking studies suggested
that the zebrafish CYP3A65, the zebrafish analogue of human
CYP3A4, was responsible for the bioactivation of Acetamino-
phen. Diclofenac is bioactivated to reactive intermediates via a
combination of both acyl glucuronide formation and CYP P450
catalysed generation of reactive quinone imine intermediates
and it has been proposed that these processes may be responsi-
ble for the drug’s propensity to cause human liver injury (Stepan
et al., 2011). As hydroxylation of Diclofenac is proven to occur in
zebrafish larvae (Alderton et al., 2010), the hepatotoxic effect in
zebrafish larvae likely results from this metabolism as well. Tac-
rine was identified, although confirmation of similar metabolic
activation is lacking, as the exact identity of the reactive metab-
olites of Tacrine are currently unknown. The mechanism ofWiley & Sons, Ltd. wileyonlinelibrary.com/journal/jat
N. Mesens et al.Tacrine-induced hepatotoxicity is thought to be CYP-P450 1A2-
mediated metabolism to a putative reactive phenol glucuronide
metabolite but this has not been confirmed to occur in patients
(www.livertox.nih.gov/Tacrine.html) and therefore requires fur-
ther investigation.
The cholestasis-inducer Bosentan did not cause detectable ef-
fects on the livers of zebrafish larvae. One of the proposed
mechanisms behind Bosentan-induced cholestasis is the inhibi-
tion of the human bile salt export pump (BSEP) as Bosentan is
a strong inhibitor of this human transporter (Fattinger et al.,
2001). Transporters are known to be species-specific and inhibi-
tion can occur at different concentrations cross-species; how-
ever, an absence of BSEP inhibition in zebrafish is unlikely as
(1) Bosentan is known to inhibit the activity of BSEP from various
species (Fattinger et al., 2001) and (2) Driessen et al. (2012)
showed histological evidence for the occurrence of cholestasis
in zebrafish adults after treatment with the model compounds
Tioacetamide, Chlorpromazine and Cyclosporine A; and BSEP in-
hibition is proposed to be at least part of the mechanism of
cholestasis-induction for these compounds (Pessayre et al.,
2008). Furthermore, Driessen et al. (2012) reported the absence
of histological features of drug-induced cholestasis in zebrafish
larvae. Drug-induced cholestasis and the apparent discrepancy
between adults and larvae thus warrant further investigation.
The remaining hepatotoxic compounds Nefazodone, Alpidem
and Troglitazone were identified by a reduced lfabp10a expres-
sion. The hepatotoxic effect of all compounds is probably multi-
factorial (encompassing reactive metabolite formation,
mitochondrial toxicity and potential transporter inhibition)
thereby hindering the elucidation of the mechanism of hepato-
toxicity in the zebrafish larvae.Ranking Power
Interestingly, whereas the hepatotoxic effect of Alpidem,
Nefazodone and Diclofenac in the zebrafish larvae occurred at
exposures close to the therapeutic dose in humans, their non-
hepatotoxic analogues Zolpidem, Buspirone and Ketorolac, re-
spectively, only induced effects at much higher concentrations
(Zolpidem and Buspirone) or no effect at all (Ketorolac). The as-
say would thus rank the chemical analogues correctly and prior-
itize the right chemical analogue for further drug development.
The couple Troglitazone and Rosiglitazone was not ranked cor-
rectly, as both compounds induced effects on the liver of the
zebrafish larvae at the same LOEL. However, including the ther-
apeutic doses did result in a larger safety window for
Rosiglitazone, as the daily dose is much lower. This might ex-
plain why Rosiglitazone is associated with a much lower fre-
quency of human hepatotoxicity compared with Troglitazone,
as hepatotoxicity of reactive metabolites is suggested to depend
on the therapeutic dose (Sakatis et al., 2012; Thompson et al.,
2012). In addition, the concurrent cardiac effects of Rosiglitazone
on the zebrafish larvae might have interfered with the true ef-
fects of Rosiglitazone on the liver. At last, it is interesting to note
that Rosiglitazone did receive an additional black box warning
for congestive heart failure and myocardial ischemia recently
(http://www.fda.gov/Drugs/DrugSafety/ucm241411.htm), which
might correlate with the observations made in this study.
Overall, we observed that 8 of the 10 hepatotoxicants were cor-
rectly identified, with the exception of Tamoxifen that exerted a
general toxic response and the cholestasis-inducer Bosentan.
Furthermore, all of these 8 hepatotoxicants exerted their effectCopyright © 2015 Johnwileyonlinelibrary.com/journal/jaton lfabp10a expression at therapeutically relevant concentrations;
these compounds would thus be correctly classified as potential
therapeutically-relevant hepatotoxicants in this assay. In contrast,
the four clean chemical analogues would be classified as having a
much lower potential for therapeutically-relevant hepatotoxicity
as their effects occurred at much higher concentrations or their
safety margins were much higher. With the regard to the different
mechanisms of DILI, the zebrafish larva seems to identify mito-
chondrial toxicity and reactive metabolite formation, and al-
though cholestasis remains to be elucidated, this implies its
applicability in assessing human relevant hepatotoxicity.
In conclusion, in this proof of concept study we have shown
that lfabp10a expression analysis in zebrafish larvae can provide
value for assessing the DILI potential of drug candidates. As DILI
is a complex toxicity, additional sets of compounds including hu-
man-specific hepatotoxicity, rodent-specific hepatotoxicity,
PPAR inducers, biliary toxicants, other organ toxicants and non-
toxicants would be needed to build a prediction model and to
understand the overall predictive capacity of the lfabp10a assay
on zebrafish larvae before the assay can be used for blind
screening of drug candidates. Moreover, in upscaling the assay
to a discovery-suitable, high-throughput mode, the use of an im-
age analysis method based on a lfabp10a reporter gene is rec-
ommended above PCR analysis on the expression of lfabp10a
because we have shown it is mandatory to include drug-induced
effects on circulation or on heart rate in the analysis, as the com-
plexity of a whole organism may not be omitted.
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